Clinical Trial Update: Efficacy & Safety of KAPVAY™ Extended-Release in Children & Adolescents With Attention Deficit Hyperactivity Disorder [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update reporting on the efficacy and safety of KAPVAY Extended-Release in children and adolescents with attention-deficit/hyperactivity d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• KAPVAY Extended-Release (guanfacine extended-release)

Snippet

Sponsor: Concordia Pharmaceuticals Inc., Barbados | Conditions: Attention Deficit Hyperactivity Disorder | Phase 4 | Status: COMPLETED | Results posted: 2014-10-15